KBY Biotech Indexv0.0.34
Search
← Pipeline|Zanutuximab

Zanutuximab

Phase 1
PIR-4762
By Pieris Pharma
Source: Trial-derived·Trials: 2
Modality
Gene Therapy
MOA
FXIai
Target
TIM-3
Pathway
Apoptosis
Cervical Ca
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
May 2019
→ Feb 2031
Phase 1Current
NCT08653596
931 pts·Cervical Ca
2019-05→2031-02·Completed
NCT04481331
535 pts·Cervical Ca
2022-03→2030-08·Completed
1,466 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-08-144.4y awayInterim· Cervical Ca
2031-02-054.9y awayInterim· Cervical Ca
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P1
Complet…
P1
Complet…
Catalysts
Interim
2030-08-14 · 4.4y away
Cervical Ca
Interim
2031-02-05 · 4.9y away
Cervical Ca
Completed|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT08653596Phase 1Cervical CaCompleted931ORR
NCT04481331Phase 1Cervical CaCompleted535BodyWt
Competitors (10)
DrugCompanyPhaseTargetMOA
NVS-6360NovartisApprovedCD38FXIai
MRK-3745Merck & CoPhase 2WRNFXIai
AZN-1715AstraZenecaPhase 3AHRFXIai
BMY-9931Bristol-Myers SquibbPhase 1GPRC5DFXIai
NVO-7877Novo NordiskPreclinicalGPRC5DFXIai
TAK-8730TakedaPhase 2VEGFFXIai
REG-6699RegeneronPhase 2/3TIM-3FcRni
SemazasiranBeiGenePhase 1PD-1FXIai
NidasacituzumabUnited TherapeuticsPhase 1/2TIM-3ALKi
PexanesiranUnited TherapeuticsPhase 1BCMAFXIai